Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Athersys Inc (ATHX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 338,002
  • Shares Outstanding, K 137,960
  • Annual Sales, $ 3,710 K
  • Annual Income, $ -32,240 K
  • 36-Month Beta -0.91
  • Price/Sales 91.15
  • Price/Cash Flow N/A
  • Price/Book 7.11

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +26.67%
on 04/26/18
2.58 -4.26%
on 05/21/18
+0.46 (+22.89%)
since 04/25/18
3-Month
1.29 +91.47%
on 03/02/18
2.58 -4.26%
on 05/21/18
+1.07 (+76.43%)
since 02/23/18
52-Week
1.29 +91.47%
on 03/02/18
2.63 -6.08%
on 10/11/17
+1.03 (+71.53%)
since 05/25/17

Most Recent Stories

More News
BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

AGLE : 10.62 (+9.26%)
BMRN : 92.49 (+4.77%)
ANIP : 62.27 (-1.06%)
ATHX : 2.47 (+0.82%)
INSYS Gets Negative FDA Recommendation for Pain Candidate

INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

AGLE : 10.62 (+9.26%)
INSY : 6.86 (-2.97%)
ANIP : 62.27 (-1.06%)
ATHX : 2.47 (+0.82%)
Moving Average Crossover Alert: Athersys, Inc. (ATHX)

Moving Average Crossover Alert: Athersys, Inc. (ATHX)

ATHX : 2.47 (+0.82%)
Biotech Market Value Set to Grow Due to Technological Advancements

According to a report by Global Market Insights, Inc., the Biotechnology Market size is projected to reach USD 775.2 billion with 9.9% CAGR by 2024. Based on technology, the industry is segmented into...

SGMO : 15.60 (-4.29%)
ATRA : 50.20 (-1.67%)
VCEL : 13.70 (-1.79%)
ATHX : 2.47 (+0.82%)
AVCO : 2.2350 (+1.59%)
Athersys Reports First Quarter 2018 Results

Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three months ended March 31, 2018.

ATHX : 2.47 (+0.82%)
UTHealth in Houston and Athersys Announce Funding for Clinical Trial using MultiStem(R) to Treat Trauma Patients

The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ:ATHX) today announced plans to conduct a Phase 2 clinical trial evaluating Athersys' MultiStem cell therapy...

ATHX : 2.47 (+0.82%)
Athersys to Host First Quarter Financial Results Call

Athersys, Inc. (Nasdaq:ATHX) will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at...

ATHX : 2.47 (+0.82%)
Athersys to Present at Needham Healthcare Conference on March 28

Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and CEO, will present a corporate overview at the 17 Annual Needham Healthcare Conference at The Westin Grand Central Hotel...

ATHX : 2.47 (+0.82%)
Healthcare Companies Capitalizing on a Resurgent Biotech Industry

FN Media Group Presents Microcapspeculators.com News Commentary

CLBS : 4.05 (+1.00%)
ABIO : 0.63 (unch)
ENDV : 0.0398 (+7.57%)
GERN : 4.70 (-2.49%)
ATHX : 2.47 (+0.82%)
Today's Research Reports on Trending Tickers: Athersys and TrovaGene

NEW YORK, NY / ACCESSWIRE / March 14, 2018 / U.S. market slumped Tuesday as technology stocks fell amid concerns of growing trade tensions between the U.S. and China. The Dow Jones Industrial Average...

TROV : 0.25 (unch)
ATHX : 2.47 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATHX with:

Business Summary

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the...

See More

Key Turning Points

2nd Resistance Point 2.53
1st Resistance Point 2.50
Last Price 2.47
1st Support Level 2.43
2nd Support Level 2.39

See More

52-Week High 2.63
Last Price 2.47
Fibonacci 61.8% 2.12
Fibonacci 50% 1.96
Fibonacci 38.2% 1.80
52-Week Low 1.29

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar